CYTK
Cytokinetics
$80.40-2.69%
Price
- Market cap
- $10 billion
- Volume
- 1.0M
- Sector
- Healthcare
Cytokinetics (CYTK) last closed at $80.40, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for CYTK, covered for search and blurred for visitors.
Performance
- 1D-1.70%
- 5D-0.90%
- 1M-7.00%
- 3M-23.27%
- 6M-5.12%
- 1Y+5.91%
- 5Y+65.51%
Financials
Over the latest four reported periods ending June 30, 2026, Cytokinetics reported revenue of $116.7 million.
The prior window totaled $3.1 million, so the latest window is higher than that stretch.
Operating cash flow in the latest window was -$541 million.
Free cash flow in the latest window was -$564.8 million.
These amounts are taken from Cytokinetics's SEC filings and are a snapshot as of August 9, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE 114.6% (0 of 100). Cash generation: FCF margin -484.0% (0 of 100). Net margin: -694.4% (0 of 100). Liquidity: Current 6.66× (100 of 100).
Cash Flow
Margins
Valuation
Valuation ratios are not in this snapshot yet.
Insights
Finorify has not written notes for CYTK in this snapshot.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.
Open CYTK in Finorify